All In Biotech

Drug Trial Radar · NCT04565236

A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

A Post Approval Commitment Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KOVALTRY in Chinese Children, Adolescents /Adults With Severe Hemophilia A

Last checked: Nov 20, 2026Latest source record: Apr 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

45

Actual

Start

Sep 22, 2020

Primary completion

Mar 15, 2024

Study completion Mar 15, 2024

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Sep 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 0 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to gather more information on safety and efficacy of Kovaltry for the prevention and treatment of bleeds in Chinese children, adolescents/adults with severe hemophilia A. In addition, pharmacokinetic parameters of Kovaltry will be assessed in a subset of patients.

Conditions

  • Hemophilia A

Interventions

  • Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1Biological

    25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months. The dose decisions are at the discretion of the investigator.

  • Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2Biological

    12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months. \>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months. The dose decisions are at the discretion of the investigator.

  • Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3Biological

    15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week. The dose decisions are at the discretion of the investigator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part ATime frame: Up to 6 months
  2. Annualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part BTime frame: Up to 48 hours post-infusion during 6 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital CAMS

    Beijing, China

  • Childrens Hospital of Shanghai

    Shanghai, China

  • Beijing Children's Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • The Children's Hospital Zhejiang University School of Med

    Hangzhou, Hangzhou Province, China

  • Shijiazhuang General Hospital

    Shijiazhuang, Hebei, China

  • NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School

    Nanjing, Jiangsu, China

  • 1st Affiliated hospital of Soochow University

    Suzhou, Jiangsu, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China

  • Children's Hospital of Shanxi

    Taiyuan, Shanxi, China

  • Chengdu Women & Children's Central Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.